RxSight, Inc. (RXST) shares increased by 6.1% on the latest trading day, closing at $5.57, backed by significant trading volume. This follows a cumulative gain of 14.4% over the past four weeks. The surge in stock price is attributed to investor optimism regarding the company’s leadership transition effective July 20, 2026, with Aziz Mottiwala taking over as President and CEO, succeeding Ron Kurtz, M.D., who remains as Chief Medical Officer.
For the upcoming quarterly report, RxSight is expected to report a loss of $0.21 per share, reflecting a year-over-year decline of 162.5%. Projected revenues are anticipated to be $32.9 million, down 2.2% from the previous year. The consensus EPS estimate has remained static over the past month, with the stock currently holding a Zacks Rank of #3 (Hold).
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
